IL-17 inhibitors target the protein called interleukin-17 (IL-17).
These biologics target either the I L-17 ligand or its receptor.
IL-17 is a cytokine, which is a type of signaling molecule involved in inflammation and immune response.
IL-17 plays a role in various autoimmune diseases, such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease.
IL-17 inhibitors work by blocking the activity of IL-17, which helps to reduce inflammation and prevent further damage to the body tissues.
These drugs effective in treating psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Some examples of IL-17 inhibitors include secukinumab, ixekizumab, bimekizumab, and brodalumab.
These drugs are typically administered by injection.